Trials / Terminated
TerminatedNCT03476369
Fentanyl and Crushed Ticagrelor in Percutaneous Coronary Intervention
A Randomized Controlled Trial of Patients Undergoing Percutaneous Coronary Intervention Who Receive Ticagrelor and Fentanyl
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- The Guthrie Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
During a percutaneous coronary intervention (PCI), Fentanyl is commonly used for sedation. Ticagrelor is also routinely used as anti-platelet agent during PCI. However, a recent study has demonstrated the decrease in effectiveness of Ticagrelor when administered along with Fentanyl. Hence this study was designed to further assess the interaction between crushed vs non crushed Ticagrelor and Fentanyl given during PCI procedures.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fentanyl | Premedicated with Fentanyl (at least 25mcg by IV) |
| DRUG | Ticagrelor 90Mg Tablet | Ticagrelor administered crushed vs non-crushed |
Timeline
- Start date
- 2018-04-18
- Primary completion
- 2025-01-23
- Completion
- 2025-01-23
- First posted
- 2018-03-26
- Last updated
- 2026-02-04
- Results posted
- 2026-02-04
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03476369. Inclusion in this directory is not an endorsement.